You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Request a visit from a Jazz representative

Learn more about clinical information and reimbursement support for VYXEOS by requesting a visit from a Jazz representative.

Simply fill out the fields below and select submit.

*Required field

Jazz Pharmaceuticals is committed to helping healthcare professionals provide appropriate care for their patients. Please provide us with the above information so that we or third parties working on our behalf can send you information, services, and materials about VYXEOS or acute myeloid leukemia. Jazz Pharmaceuticals will not sell or provide your personal information to other parties without your permission. For more information about how Jazz Pharmaceuticals protects your personal information, please click here to view our Privacy Statement. If you prefer not to receive further email communications from Jazz Pharmaceuticals, please click here to unsubscribe.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.